InvestorsHub Logo
Followers 16
Posts 4837
Boards Moderated 1
Alias Born 06/27/2003

Re: None

Tuesday, 06/02/2020 10:32:21 AM

Tuesday, June 02, 2020 10:32:21 AM

Post# of 645
AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer
June 02 2020 - 09:00AM
PR Newswire (US) Print
ATLANTA, June 2, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that its proposed amalgamation partner Jay Pharma Inc. ("Jay Pharma") received institutional review board ("IRB") approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma's proprietary cannabidiol ("CBD") formulation for the treatment of glioblastoma multiforme ("GBM"), a rare and aggressive form of brain cancer. This open-label, two-arm, randomized, prospective study is scheduled to commence following final approval from the Israel Ministry of Health, which is expected this summer.